The Peripheral Versus Central Antinociception of a Novel Opioid Agonist: Acute Inflammatory Pain in Rats

Mihály Balogh, Z. Zádori, Bernadette Lázár, Dávid Karádi, Szilvia László, Shaaban A. Mousa, Sándor Hosztafi, Ferenc Zádor, P. Riba, Michael Schäfer, S. Fürst, M. Al-Khrasani

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Opioid analgesics devoid of central side effects are unmet medical need in the treatment of acute pain (e.g. post-operative pain). Recently, we have reported on 14-O-methylmorphine-6-O-sulfate (14-O-MeM6SU), a novel opioid agonist of high efficacy producing peripheral antinociception in subchronic inflammatory pain in certain doses. The present study focused on the antinociceptive effect of 14-O-MeM6SU compared to morphine in formalin test of an early/acute (Phase I) and late/tonic (Phase II) pain phases. Subcutaneous 14-O-MeM6SU (253–1012 nmol/kg) and morphine (3884–31075 nmol/kg) dose dependently reduced the pain behaviors of both phases. Co-administered naloxone methiodide (NAL-M), a peripherally acting opioid antagonist, abolished the antinociceptive effect of 506 nmol/kg 14-O-MeM6SU. On the other hand, the effects of 14-O-MeM6SU (1012 nmol/kg) and morphine (15538 nmol/kg) were only partially affected by NAL-M, indicating the contribution of CNS to antinociception. Locally injected test compounds into formalin treated paws caused antinociception in both phases. Locally effective doses of test compounds were also injected into contralateral paws. Morphine showed effects in both phases, 14-O-MeM6SU in certain doses failed to produce antinociception in either phase. A NAL-M reversible systemic dose of 14-O-MeM6SU and the lowest systemic effective dose of morphine were evaluated for their sedative effects following isoflurane-induced sleeping (righting reflex). In contrast to morphine, 14-O-MeM6SU in certain antinociceptive doses showed no impact on sleeping time. These data highlight that high efficacy opioids of limited CNS penetration in certain doses mitigate somatic and inflammatory pain by targeting MOR at the periphery.

Original languageEnglish
Pages (from-to)1-8
Number of pages8
JournalNeurochemical Research
DOIs
Publication statusAccepted/In press - May 3 2018

Fingerprint

Acute Pain
Opioid Analgesics
Rats
Morphine
Pain
Formaldehyde
Righting Reflex
Nociceptive Pain
Narcotic Antagonists
14-O-methylmorphine-6-O-sulfate
Isoflurane
Pain Measurement
Hypnotics and Sedatives
N-methylnaloxone

Keywords

  • 14-O-methylmorphine-6-O-sulfate
  • Antinociception
  • CNS
  • Opioids
  • Peripheral

ASJC Scopus subject areas

  • Biochemistry
  • Cellular and Molecular Neuroscience

Cite this

The Peripheral Versus Central Antinociception of a Novel Opioid Agonist : Acute Inflammatory Pain in Rats. / Balogh, Mihály; Zádori, Z.; Lázár, Bernadette; Karádi, Dávid; László, Szilvia; Mousa, Shaaban A.; Hosztafi, Sándor; Zádor, Ferenc; Riba, P.; Schäfer, Michael; Fürst, S.; Al-Khrasani, M.

In: Neurochemical Research, 03.05.2018, p. 1-8.

Research output: Contribution to journalArticle

Balogh, Mihály ; Zádori, Z. ; Lázár, Bernadette ; Karádi, Dávid ; László, Szilvia ; Mousa, Shaaban A. ; Hosztafi, Sándor ; Zádor, Ferenc ; Riba, P. ; Schäfer, Michael ; Fürst, S. ; Al-Khrasani, M. / The Peripheral Versus Central Antinociception of a Novel Opioid Agonist : Acute Inflammatory Pain in Rats. In: Neurochemical Research. 2018 ; pp. 1-8.
@article{651bb30bafdd4038a869029f39e4cdcb,
title = "The Peripheral Versus Central Antinociception of a Novel Opioid Agonist: Acute Inflammatory Pain in Rats",
abstract = "Opioid analgesics devoid of central side effects are unmet medical need in the treatment of acute pain (e.g. post-operative pain). Recently, we have reported on 14-O-methylmorphine-6-O-sulfate (14-O-MeM6SU), a novel opioid agonist of high efficacy producing peripheral antinociception in subchronic inflammatory pain in certain doses. The present study focused on the antinociceptive effect of 14-O-MeM6SU compared to morphine in formalin test of an early/acute (Phase I) and late/tonic (Phase II) pain phases. Subcutaneous 14-O-MeM6SU (253–1012 nmol/kg) and morphine (3884–31075 nmol/kg) dose dependently reduced the pain behaviors of both phases. Co-administered naloxone methiodide (NAL-M), a peripherally acting opioid antagonist, abolished the antinociceptive effect of 506 nmol/kg 14-O-MeM6SU. On the other hand, the effects of 14-O-MeM6SU (1012 nmol/kg) and morphine (15538 nmol/kg) were only partially affected by NAL-M, indicating the contribution of CNS to antinociception. Locally injected test compounds into formalin treated paws caused antinociception in both phases. Locally effective doses of test compounds were also injected into contralateral paws. Morphine showed effects in both phases, 14-O-MeM6SU in certain doses failed to produce antinociception in either phase. A NAL-M reversible systemic dose of 14-O-MeM6SU and the lowest systemic effective dose of morphine were evaluated for their sedative effects following isoflurane-induced sleeping (righting reflex). In contrast to morphine, 14-O-MeM6SU in certain antinociceptive doses showed no impact on sleeping time. These data highlight that high efficacy opioids of limited CNS penetration in certain doses mitigate somatic and inflammatory pain by targeting MOR at the periphery.",
keywords = "14-O-methylmorphine-6-O-sulfate, Antinociception, CNS, Opioids, Peripheral",
author = "Mih{\'a}ly Balogh and Z. Z{\'a}dori and Bernadette L{\'a}z{\'a}r and D{\'a}vid Kar{\'a}di and Szilvia L{\'a}szl{\'o} and Mousa, {Shaaban A.} and S{\'a}ndor Hosztafi and Ferenc Z{\'a}dor and P. Riba and Michael Sch{\"a}fer and S. F{\"u}rst and M. Al-Khrasani",
year = "2018",
month = "5",
day = "3",
doi = "10.1007/s11064-018-2542-7",
language = "English",
pages = "1--8",
journal = "Neurochemical Research",
issn = "0364-3190",
publisher = "Springer New York",

}

TY - JOUR

T1 - The Peripheral Versus Central Antinociception of a Novel Opioid Agonist

T2 - Acute Inflammatory Pain in Rats

AU - Balogh, Mihály

AU - Zádori, Z.

AU - Lázár, Bernadette

AU - Karádi, Dávid

AU - László, Szilvia

AU - Mousa, Shaaban A.

AU - Hosztafi, Sándor

AU - Zádor, Ferenc

AU - Riba, P.

AU - Schäfer, Michael

AU - Fürst, S.

AU - Al-Khrasani, M.

PY - 2018/5/3

Y1 - 2018/5/3

N2 - Opioid analgesics devoid of central side effects are unmet medical need in the treatment of acute pain (e.g. post-operative pain). Recently, we have reported on 14-O-methylmorphine-6-O-sulfate (14-O-MeM6SU), a novel opioid agonist of high efficacy producing peripheral antinociception in subchronic inflammatory pain in certain doses. The present study focused on the antinociceptive effect of 14-O-MeM6SU compared to morphine in formalin test of an early/acute (Phase I) and late/tonic (Phase II) pain phases. Subcutaneous 14-O-MeM6SU (253–1012 nmol/kg) and morphine (3884–31075 nmol/kg) dose dependently reduced the pain behaviors of both phases. Co-administered naloxone methiodide (NAL-M), a peripherally acting opioid antagonist, abolished the antinociceptive effect of 506 nmol/kg 14-O-MeM6SU. On the other hand, the effects of 14-O-MeM6SU (1012 nmol/kg) and morphine (15538 nmol/kg) were only partially affected by NAL-M, indicating the contribution of CNS to antinociception. Locally injected test compounds into formalin treated paws caused antinociception in both phases. Locally effective doses of test compounds were also injected into contralateral paws. Morphine showed effects in both phases, 14-O-MeM6SU in certain doses failed to produce antinociception in either phase. A NAL-M reversible systemic dose of 14-O-MeM6SU and the lowest systemic effective dose of morphine were evaluated for their sedative effects following isoflurane-induced sleeping (righting reflex). In contrast to morphine, 14-O-MeM6SU in certain antinociceptive doses showed no impact on sleeping time. These data highlight that high efficacy opioids of limited CNS penetration in certain doses mitigate somatic and inflammatory pain by targeting MOR at the periphery.

AB - Opioid analgesics devoid of central side effects are unmet medical need in the treatment of acute pain (e.g. post-operative pain). Recently, we have reported on 14-O-methylmorphine-6-O-sulfate (14-O-MeM6SU), a novel opioid agonist of high efficacy producing peripheral antinociception in subchronic inflammatory pain in certain doses. The present study focused on the antinociceptive effect of 14-O-MeM6SU compared to morphine in formalin test of an early/acute (Phase I) and late/tonic (Phase II) pain phases. Subcutaneous 14-O-MeM6SU (253–1012 nmol/kg) and morphine (3884–31075 nmol/kg) dose dependently reduced the pain behaviors of both phases. Co-administered naloxone methiodide (NAL-M), a peripherally acting opioid antagonist, abolished the antinociceptive effect of 506 nmol/kg 14-O-MeM6SU. On the other hand, the effects of 14-O-MeM6SU (1012 nmol/kg) and morphine (15538 nmol/kg) were only partially affected by NAL-M, indicating the contribution of CNS to antinociception. Locally injected test compounds into formalin treated paws caused antinociception in both phases. Locally effective doses of test compounds were also injected into contralateral paws. Morphine showed effects in both phases, 14-O-MeM6SU in certain doses failed to produce antinociception in either phase. A NAL-M reversible systemic dose of 14-O-MeM6SU and the lowest systemic effective dose of morphine were evaluated for their sedative effects following isoflurane-induced sleeping (righting reflex). In contrast to morphine, 14-O-MeM6SU in certain antinociceptive doses showed no impact on sleeping time. These data highlight that high efficacy opioids of limited CNS penetration in certain doses mitigate somatic and inflammatory pain by targeting MOR at the periphery.

KW - 14-O-methylmorphine-6-O-sulfate

KW - Antinociception

KW - CNS

KW - Opioids

KW - Peripheral

UR - http://www.scopus.com/inward/record.url?scp=85046495905&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85046495905&partnerID=8YFLogxK

U2 - 10.1007/s11064-018-2542-7

DO - 10.1007/s11064-018-2542-7

M3 - Article

C2 - 29725918

AN - SCOPUS:85046495905

SP - 1

EP - 8

JO - Neurochemical Research

JF - Neurochemical Research

SN - 0364-3190

ER -